William Blair Comments on Exagen's Q2 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN - Free Report) - Equities researchers at William Blair dropped their Q2 2025 EPS estimates for shares of Exagen in a research note issued on Monday, May 5th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.18) for the quarter, down from their prior estimate of ($0.16). William Blair has a "Outperform" rating on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen's Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.25) EPS.

Other research analysts have also issued reports about the company. Canaccord Genuity Group upped their target price on Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 price objective on shares of Exagen in a research note on Monday, January 13th. Finally, BTIG Research reiterated a "buy" rating on shares of Exagen in a research report on Wednesday, May 7th.

Exagen Stock Performance

Shares of XGN stock traded down $0.12 during mid-day trading on Thursday, reaching $5.65. The stock had a trading volume of 242,872 shares, compared to its average volume of 109,580. Exagen has a one year low of $1.49 and a one year high of $7.20. The firm has a market cap of $101.71 million, a PE ratio of -6.01 and a beta of 1.50. The firm's 50 day simple moving average is $4.60 and its 200 day simple moving average is $4.15. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The business had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share.

Institutional Investors Weigh In On Exagen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Toronto Dominion Bank acquired a new position in Exagen in the fourth quarter worth $3,655,000. Driehaus Capital Management LLC bought a new position in shares of Exagen in the fourth quarter valued at about $1,716,000. Kennedy Capital Management LLC lifted its position in Exagen by 8.8% during the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock worth $756,000 after buying an additional 14,920 shares in the last quarter. Palumbo Wealth Management LLC grew its holdings in Exagen by 14.4% during the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock worth $356,000 after acquiring an additional 12,501 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock valued at $402,000 after acquiring an additional 10,442 shares in the last quarter. 75.25% of the stock is owned by institutional investors and hedge funds.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).